HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX

Halozyme Therapeutics announced an expansion of its collaboration with argenx, increasing exclusive ENHANZE technology targets from six to eight. The deal includes milestone payments and royalties on product sales. Halozyme raised its 2026 revenue guidance to $1.84-$1.91 billion, driven by strong royalty growth from J&J's Darzalex and argenx's Vyvgart Hytrulo.